A digital musculoskeletal care company that treats joint and muscle pain for employers and health plans, pairing personalized exercise therapy with AI motion tracking (TrueMotion) and an FDA-cleared wearable pain device (Enso). It was founded in 2014 by two PhD students who met in the UK — one recovering from a broken leg in a biking accident, the other from a judo ligament tear. Its name comes from the body's "hinge joints," like the knee and elbow, the very parts it aims to keep moving.
Hinge Health posts its highest quarterly revenue and operating margin as a public company, with Q2 revenue up 53% to $212.8M.
Hinge Health reached a new scale in Q2. rose 53% to $212.8 million and widened to 19.0%, driven entirely by growth within existing clients as expanded to 86.4%. The company is now generating substantial cash and deploying it for acquisitions and buybacks, even as customer concentration remains a central risk.
Key takeaways
rose 53% to $212.8 million, driven entirely by retaining and adding members within existing clients contracted in 2025 or earlier.
expanded to 86.4% from 70.3% a year ago, which management attributed to a $15.3 million drop in within cost of and improved care team efficiency.
was $40.4 million, a 19.0% margin, compared to a $580.7 million loss in the same quarter last year when a $571.4 million IPO-related charge was recorded.
was $101.3 million, up from $20.0 million a year ago, supported by a $101.4 million operating cash inflow.
The company announced a definitive agreement to acquire Cylinder Health, Inc., expected to close in Q3 2026, to add an integrated Gastrointestinal Care Program in 2027.
The top three health plan partners accounted for 38% of in the first half of 2026, and their contracts are terminable for convenience.
What changed
The FDA inquiry into the TrueMotion AI technology, flagged in prior quarters, reappeared in this quarter's risk factors as an ongoing exposure that could lead to enforcement or require new clearances.
The trajectory of , previously watched to assess underlying , is now reflected in a operating margin that reached 19.0%, up from 17.6% in Q1 2026.
The $250 million program continued: $131.5 million was used in the first half of 2026, leaving $118.5 million remaining on the authorization, compared to $80 million remaining after Q1.
What to watch
Whether the Cylinder Health acquisition closes in Q3 2026 as expected and what purchase price and integration costs are disclosed.
Client retention and renewal rates as the engagement-based pricing model expands into fully insured health plans and Medicare Advantage, given that 38% of H1 came from three partners with contracts terminable for convenience.
Whether the remaining $118.5 million on the authorization is exhausted and at what average price, and whether the board authorizes a new program.
Section summaries
Management's Discussion and Analysis
Revenue rose 53% YoY to $212.8M in Q2 FY2026, driven by existing client growth, while gross margin expanded to 86% on lower stock-based compensation.
⌄
grew 53% to $212.8M in Q2 FY2026, primarily from retaining and adding members within existing clients contracted in 2025 or earlier.
expanded to 86% from 70% , driven by a $15.3M drop in in cost of and improved care team efficiency.
widened further to 86.4% from 84.6% in the prior quarter, suggesting the efficiencies flagged in Q1 are persisting rather than reflecting a one-time mix shift.
Any resolution or escalation of the FDA inquiry into the TrueMotion AI technology, which reappeared in this quarter's risk factors.
Total operating expenses fell 88% to $143.5M, largely due to a $571.9M decline in tied to IPO-related RSU and PRSU vesting in Q2 2025.
Sales and marketing expenses decreased 45% to $81.4M, but underlying cash costs rose, including a $13.3M increase in marketing and promotion and $9.5M in commissions.
was $99.6M in Q2 FY2026, and the company repurchased $131.5M of Class A common stock in H1 FY2026 under its program.
The company announced a definitive agreement to acquire Cylinder Health, Inc., expected to close in Q3 2026, to add an integrated Gastrointestinal Care Program in 2027.
Quantitative and Qualitative Disclosures About Market Risk
Interest-rate risk is the primary market exposure; a hypothetical 10% rate change would have a $0.8M impact on operations.
⌄
Cash, equivalents, and totaled $474.1M as of June 30, 2026, held in money market accounts, U.S. Treasuries, investment-grade corporate bonds, government agency securities, and .
The company does not hold any financial instruments for trading or speculative purposes.
A hypothetical 10% change in U.S. interest rates would have a $0.8 million impact on the statement of operations for the six months ended June 30, 2026.
Foreign-currency exposure arises mainly from employees and vendors in India and Canada, but the company does not currently this risk because it affects only a small portion of expenses.
A 10% adverse move in exchange rates would not have a material impact on the financial statements as of June 30, 2026.
From time to time, we may be involved in various legal proceedings or subject to claims and investigations in the ordinary course of business. We are not presently a party to any litigation to which the outcome, we believe, if determined adversely to us, would individually or ta…
⌄
From time to time, we may be involved in various legal proceedings or subject to claims and investigations in the ordinary course of business. We are not presently a party to any litigation to which the outcome, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, or financial condition. Future litigation may be necessary to defend ourselves and our clients by determining the scope, enforceability, and validity of third-party proprietary rights, to establish our proprietary rights, or for other matters. Involvement in such proceedings is costly and can impose a significant burden on management and employees. We cannot predict the results of any such proceedings, claims, or investigations, and despite the potential outcomes, the existence thereof may have a material adverse impact on us due to diversion of management time and attention as well as the financial costs related to resolving such matters.
The company faces material risks from its history of net losses, heavy reliance on a few health plan partners, and expansion into new, uncertain areas like migraine care and AI.
⌄
The company has a history of significant net losses and an of $1.0 billion, with no assurance of achieving or maintaining profitability.
A substantial majority of is concentrated through a few health plan partners; the top three partners (HCSC, Elevance, Aetna) accounted for 38% of revenue in H1 2026, and their contracts are terminable for convenience.
Expansion into new business areas, including the migraine care program and the HingeSelect surgery network, introduces significant clinical, regulatory, and commercial risks with a limited operating history.
The increasing use of AI and machine learning technologies exposes the company to risks of inaccurate outputs, evolving and uncertain regulations (e.g., EU AI Act, state laws), and potential liability.
The company's Enso device and digital platform are subject to extensive FDA and international medical device regulations, and a recent FDA inquiry into its AI-powered TrueMotion technology could lead to enforcement or require new clearances.
The dual-class stock structure concentrates voting control with Class B stockholders, including founders, which may limit the influence of Class A stockholders and potentially depress the stock price.